WuXi Biologics (Cayman) (SEHK:2269) Wins FDA Inspection As Its Undervalued Case Builds

Simply Wall St.07-12 03:20

WuXi Biologics (Cayman) (SEHK:2269) is back in focus after its MFG8 facility in Hebei cleared a seven day U.S. FDA Pre License Inspection, supporting commercial production of a potential autoimmune ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2650526661?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-07-12 03:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650526661","market":"sg","top_or_hot":-1,"title":"WuXi Biologics (Cayman) (SEHK:2269) Wins FDA Inspection As Its Undervalued Case Builds","media":"Simply Wall St.","content":"<div>\n<p>WuXi Biologics (Cayman) (SEHK:2269) is back in focus after its MFG8 facility in Hebei cleared a seven day U.S. FDA Pre License Inspection, supporting commercial production of a potential autoimmune ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/wuxi-biologics-cayman-sehk2269-wins-fda-inspection-as-its-un\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WuXi Biologics (Cayman) (SEHK:2269) Wins FDA Inspection As Its Undervalued Case Builds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuXi Biologics (Cayman) (SEHK:2269) Wins FDA Inspection As Its Undervalued Case Builds\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-12 03:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/wuxi-biologics-cayman-sehk2269-wins-fda-inspection-as-its-un><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WuXi Biologics (Cayman) (SEHK:2269) is back in focus after its MFG8 facility in Hebei cleared a seven day U.S. FDA Pre License Inspection, supporting commercial production of a potential autoimmune ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/wuxi-biologics-cayman-sehk2269-wins-fda-inspection-as-its-un\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0572944931.SGD","symbol_name":"Janus Henderson Horizon China Opportunities A2 SGD","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/wuxi-biologics-cayman-sehk2269-wins-fda-inspection-as-its-un","article_id":"2650526661","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/wuxi-biologics-cayman-sehk2269-wins-fda-inspection-as-its-un","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2650526661","pubTimestamp":1783797611,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"WuXi Biologics (Cayman) (SEHK:2269) is back in focus after its MFG8 facility in Hebei cleared a seven day U.S. FDA Pre License Inspection, supporting commercial production of a potential autoimmune therapy.\nSee our latest analysis for WuXi Biologics (Cayman).\nAt a share price of HK$37.96, WuXi Biologics (Cayman) has seen a 26.79% 30 day share price return and a 16.66% year to date share price return. Its 1 year total shareholder return of 42.44% contrasts with weaker multi year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","BK1610":"ETF&股票定投概念","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LABU":"三倍做多标普生物-Direxion","02269":"药明生物","BK1141":"生命科学工具和服务","LU0052750758.USD":"富兰克林中国基金A Acc","LU0051755006.USD":"摩根大通中国A (dist)","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","KURE":"KraneShares MSCI All China Health Care Index ETF","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU0823426308.USD":"法巴中国股票基金","BK4585":"ETF&股票定投概念","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","BK1521":"挪威政府全球养老基金持仓","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0823426480.USD":"法巴中国股票经典Dis","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU1720050803.USD":"安联全方位中国股票基金","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","BK1589":"北水核心资产","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","BK4588":"碎股","LU0359201612.USD":"贝莱德中国基金A2","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","SG9999002463.SGD":"LionGlobal China Growth SGD","BK1576":"医药外包概念"},"translate_title":"药明生物 (Cayman) (SEHK:2269) 赢得 FDA 检查，其被低估的案件不断增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"02269":0.9,"KURE":0.6},"content_text":"WuXi Biologics (Cayman) (SEHK:2269) is back in focus after its MFG8 facility in Hebei cleared a seven day U.S. FDA Pre License Inspection, supporting commercial production of a potential autoimmune therapy. See our latest analysis for WuXi Biologics (Cayman). At a share price of HK$37.96, WuXi Biologics (Cayman) has seen a 26.79% 30 day share price return and a 16.66% year to date share price return. Its 1 year total shareholder return of 42.44% contrasts with weaker multi year total shareholder returns and points to momentum rebuilding around a series of recent regulatory wins. If this kind of regulatory driven shift has your attention, it could be a moment to scan other healthcare names using our screener for 130 healthcare AI stocks The sharp rebound in WuXi Biologics (Cayman) after the MFG8 inspection success can be read as a re rating of its quality track record, or as sentiment snapping back after a weak few years. How does current pricing line up with that backdrop? AdvertisementMost Popular Narrative: 19% Undervalued WuXi Biologics (Cayman) last closed at HK$37.96, while the most widely followed narrative places fair value at about HK$46.88, using a detailed earnings and cash flow roadmap built on analyst assumptions.  The accelerated ramp in ADC (antibody drug conjugates) and bispecific/multi specific project wins, now making up over 40% of WuXi Biologics' portfolio and driving new, high complexity business, positions the company as the partner of choice in these fast growing biologics segments. This supports sustained backlog growth and provides strong visibility into higher late stage and manufacturing revenues over the next 3 to 5 years.  Read the complete narrative. Want to see what kind of revenue compounding, margin profile and future earnings multiple analysts are baking in to justify that higher fair value? The full narrative lays out how growth in complex biologics, mix shift toward higher margin work and a premium earnings multiple are combined into a single HK$46.88 figure, along with the discount rate that ties all those future numbers back to today. Result: Fair Value of HK$46.88 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, investors in WuXi Biologics (Cayman) still need to weigh exposure to geopolitical and regulatory shifts, and the risk that global biopharma clients may source more work elsewhere. Find out about the key risks to this WuXi Biologics (Cayman) narrative. Next Steps Given the mix of optimism and caution around WuXi Biologics (Cayman), it makes sense to look at the underlying data yourself and move decisively once you are comfortable. To see the specific factors driving the more optimistic view, start with the 3 key rewards. Looking for more investment ideas beyond WuXi Biologics (Cayman)? If WuXi Biologics (Cayman) has sharpened your interest in opportunity and risk, do not stop here. Broaden your watchlist now using focused stock screeners.  Spot potential bargains early by scanning companies that combine quality fundamentals with attractive pricing through the 211 high quality undervalued stocks. Build a steadier portfolio by searching for income focused stocks in the 472 dividend fortresses. Sleep easier at night by checking stocks that score well on resilience and financial strength in the 295 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if WuXi Biologics (Cayman) might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650526661","isCrawlerRequest":true}